Principal Financial Group Inc. Lowers Stock Position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

Principal Financial Group Inc. cut its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 4.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 756,707 shares of the company's stock after selling 34,427 shares during the period. Principal Financial Group Inc. owned 1.32% of Structure Therapeutics worth $13,099,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in shares of Structure Therapeutics during the 4th quarter valued at $34,000. Virtus ETF Advisers LLC raised its position in shares of Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after purchasing an additional 455 shares during the period. Assetmark Inc. raised its position in shares of Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after purchasing an additional 953 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Structure Therapeutics by 673.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after purchasing an additional 3,549 shares during the period. Finally, Headlands Technologies LLC bought a new stake in shares of Structure Therapeutics during the 4th quarter valued at $113,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock traded down $0.02 during trading hours on Monday, reaching $19.00. The company's stock had a trading volume of 111,623 shares, compared to its average volume of 830,595. The firm has a 50 day moving average price of $22.42 and a 200-day moving average price of $23.04. Structure Therapeutics Inc. Sponsored ADR has a one year low of $13.22 and a one year high of $47.48. The stock has a market cap of $1.09 billion, a P/E ratio of -22.00 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GPCR has been the topic of several recent analyst reports. Citigroup assumed coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, June 23rd. HC Wainwright reduced their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $89.00 price target on shares of Structure Therapeutics in a report on Monday, June 23rd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $76.17.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.